OF298621
KR 1020210131855-A/3: A pharmaceutical compositon for treating lung cancer comprising R-point regulatory protein complex as an active ingredient, a screening method for treating lung cancer using the formation of the complex, and a method for diagnosing lung cancer.
18
RNA
synthetic construct
OF298626
KR 1020210131855-A/8: A pharmaceutical compositon for treating lung cancer comprising R-point regulatory protein complex as an active ingredient, a screening method for treating lung cancer using the formation of the complex, and a method for diagnosing lung cancer.
19
RNA
synthetic construct
OF298620
KR 1020210131855-A/2: A pharmaceutical compositon for treating lung cancer comprising R-point regulatory protein complex as an active ingredient, a screening method for treating lung cancer using the formation of the complex, and a method for diagnosing lung cancer.
19
RNA
synthetic construct
OF298625
KR 1020210131855-A/7: A pharmaceutical compositon for treating lung cancer comprising R-point regulatory protein complex as an active ingredient, a screening method for treating lung cancer using the formation of the complex, and a method for diagnosing lung cancer.
19
RNA
synthetic construct
OF298630
KR 1020210131855-A/12: A pharmaceutical compositon for treating lung cancer comprising R-point regulatory protein complex as an active ingredient, a screening method for treating lung cancer using the formation of the complex, and a method for diagnosing lung cancer.
23
DNA
synthetic construct
OF756628
KR 1020210131855-A/17: A pharmaceutical compositon for treating lung cancer comprising R-point regulatory protein complex as an active ingredient, a screening method for treating lung cancer using the formation of the complex, and a method for diagnosing lung cancer.
415
PRT
synthetic construct
OF756629
KR 1020210131855-A/19: A pharmaceutical compositon for treating lung cancer comprising R-point regulatory protein complex as an active ingredient, a screening method for treating lung cancer using the formation of the complex, and a method for diagnosing lung cancer.
801
PRT
synthetic construct
OF756630
KR 1020210131855-A/21: A pharmaceutical compositon for treating lung cancer comprising R-point regulatory protein complex as an active ingredient, a screening method for treating lung cancer using the formation of the complex, and a method for diagnosing lung cancer.
3972
PRT
synthetic construct
OF298623
KR 1020210131855-A/5: A pharmaceutical compositon for treating lung cancer comprising R-point regulatory protein complex as an active ingredient, a screening method for treating lung cancer using the formation of the complex, and a method for diagnosing lung cancer.
19
RNA
synthetic construct
OF298628
KR 1020210131855-A/10: A pharmaceutical compositon for treating lung cancer comprising R-point regulatory protein complex as an active ingredient, a screening method for treating lung cancer using the formation of the complex, and a method for diagnosing lung cancer.
19
RNA
synthetic construct
OF298619
KR 1020210131855-A/1: A pharmaceutical compositon for treating lung cancer comprising R-point regulatory protein complex as an active ingredient, a screening method for treating lung cancer using the formation of the complex, and a method for diagnosing lung cancer.
19
RNA
synthetic construct
OF298624
KR 1020210131855-A/6: A pharmaceutical compositon for treating lung cancer comprising R-point regulatory protein complex as an active ingredient, a screening method for treating lung cancer using the formation of the complex, and a method for diagnosing lung cancer.
20
RNA
synthetic construct
OF298629
KR 1020210131855-A/11: A pharmaceutical compositon for treating lung cancer comprising R-point regulatory protein complex as an active ingredient, a screening method for treating lung cancer using the formation of the complex, and a method for diagnosing lung cancer.
23
DNA
synthetic construct
OF298622
KR 1020210131855-A/4: A pharmaceutical compositon for treating lung cancer comprising R-point regulatory protein complex as an active ingredient, a screening method for treating lung cancer using the formation of the complex, and a method for diagnosing lung cancer.
19
RNA
synthetic construct
OF298627
KR 1020210131855-A/9: A pharmaceutical compositon for treating lung cancer comprising R-point regulatory protein complex as an active ingredient, a screening method for treating lung cancer using the formation of the complex, and a method for diagnosing lung cancer.
19
RNA
synthetic construct
DI181561
KR 1020090098677-A/11: Method for Detecting Lung Cancer Using Lung Cancer Specific Methylated Marker Gene.
21
DNA
artificial sequences
DI181569
KR 1020090098677-A/19: Method for Detecting Lung Cancer Using Lung Cancer Specific Methylated Marker Gene.
20
DNA
artificial sequences
HV444575
JP 2011515081-A/9: Method for detecting lung cancer using lung cancer-specific methylation marker gene.
28
DNA
synthetic construct
HV444583
JP 2011515081-A/17: Method for detecting lung cancer using lung cancer-specific methylation marker gene.
22
DNA
synthetic construct
HW615993
JP 2014168434-A/2: Prediction-inspection method of efficacy of lung cancer treatment and Screening method for lung cancer drug.
25
RNA
synthetic construct
HZ489205
JP 2016015948-A/3: METHODFOR OBTAINING INFORMATION ON LUNG CANCER, AND MARKERS AND KIT FOR OBTAINING INFORMATION ON LUNG CANCER.
118
DNA
synthetic construct
HW615992
JP 2014168434-A/1: Prediction-inspection method of efficacy of lung cancer treatment and Screening method for lung cancer drug.
25
RNA
synthetic construct
HZ489212
JP 2016015948-A/10: METHODFOR OBTAINING INFORMATION ON LUNG CANCER, AND MARKERS AND KIT FOR OBTAINING INFORMATION ON LUNG CANCER.
21
DNA
synthetic construct
HV444573
JP 2011515081-A/7: Method for detecting lung cancer using lung cancer-specific methylation marker gene.
25
DNA
synthetic construct
HV444581
JP 2011515081-A/15: Method for detecting lung cancer using lung cancer-specific methylation marker gene.
23
DNA
synthetic construct
DI181555
KR 1020090098677-A/5: Method for Detecting Lung Cancer Using Lung Cancer Specific Methylated Marker Gene.
30
DNA
artificial sequences
DI181563
KR 1020090098677-A/13: Method for Detecting Lung Cancer Using Lung Cancer Specific Methylated Marker Gene.
22
DNA
artificial sequences
DI181571
KR 1020090098677-A/21: Method for Detecting Lung Cancer Using Lung Cancer Specific Methylated Marker Gene.
19
DNA
artificial sequences
DI181560
KR 1020090098677-A/10: Method for Detecting Lung Cancer Using Lung Cancer Specific Methylated Marker Gene.
30
DNA
artificial sequences
DI181568
KR 1020090098677-A/18: Method for Detecting Lung Cancer Using Lung Cancer Specific Methylated Marker Gene.
19
DNA
artificial sequences